---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ONWARD2"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ONWARD2. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 23 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/onward2"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ONWARD2

<a id="heading-3.1.2"></a>

## 3.1.2 ONWARD2

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Objective in the brief title of the ClinicalTrials.gov record

> “A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001”

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study start and completion dates in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2024-08-20” |
| Primary completion (actual) | “2025-09-23” |
| Study completion (actual) | “2025-12-18” |
| First submitted | “2024-09-07” |
| Last update posted | “2026-10-28” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.2-2"></a>

#### Completion dates estimated at registration, September 2024, superseded in June 2025

| Field | Quoted record |
| --- | --- |
| Primary completion | “2026-05 [Estimated]” |
| Study completion | “2026-06 [Estimated]” |

Source: [ClinicalTrials.gov NCT06588738 version 1](https://clinicaltrials.gov/study/NCT06588738?tab=history&a=1)

<a id="topic-3.1.2.2-3"></a>

#### Results posting status and certification date in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Results | “No Results Posted” |
| Certification/extension first submitted | “2026-08-06” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.2-4"></a>

#### Countries of trial sites in the ClinicalTrials.gov record

> “This study has 124 locations”

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

| Country | First site listed for the country in the record |
| --- | --- |
| United States | “Birmingham, Alabama, United States, 35203” |
| Austria | “Vienna, Austria, 1220” |
| Canada | “Calgary, Alberta, Canada, T3E 0B2” |
| Estonia | “Tallinn, Estonia, 10128” |
| France | “Nice, France, 06000” |
| Germany | “Berlin, Germany, 10789” |
| Hungary | “Budapest, Hungary, 1152” |
| Israel | “Ramat Gan, Israel, 526200” |
| Latvia | “Riga, Latvia, LV1001” |
| Poland | “Katowice, Poland, 40-568” |
| Puerto Rico | “Caguas, Puerto Rico, 00725” |
| Spain | “Alicante, Spain, 3010” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.2-5"></a>

#### Countries listed for ESK-001-017 in the topline webcast presentation

> “(ESK - 001 - 017) Germany France Estonia Canada Austria Romania Puerto Rico Poland Latvia Hungary United Kingdom United States Israel Spain”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)”

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Age and sex | “Males or females, age ≥18 years” |
| Disease duration | “Diagnosis of plaque psoriasis for ≥6 months” |
| Body surface area | “Plaques covering ≥10% of BSA” |
| PASI | “PASI ≥12” |
| sPGA | “sPGA ≥3” |
| Contraception | “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.4-2"></a>

#### Exclusion criteria on psoriasis type, associated conditions, and pregnancy in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Psoriasis type | “Nonplaque psoriasis or other inflammatory skin conditions” |
| Associated immune-mediated conditions | “Immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Patients with psoriatic arthritis may participate” |
| Pregnancy | “Pregnant, lactating, or planning to get pregnant during the study” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.4-3"></a>

#### Washout periods and prior treatment response in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Topical therapy | “Topical within 2 weeks” |
| Phototherapy or systemic therapy | “Phototherapy or any systemic treatments within 4 weeks” |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months” |
| Systemic immunosuppressants | “Systemic immunosuppressants or immunomodulatory drugs within 4 weeks” |
| B-cell and T-cell modulators | “Modulators of B cells within 6 months, or T cells within 3 months” |
| JAK and TYK2 inhibitors | “JAK inhibitors or TYK2 inhibitors within 4 weeks” |
| PDE4 inhibitors | “PDE4 inhibitor within 2 months” |
| Investigational agents | “Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study” |
| Prior treatment response | “Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.4-4"></a>

#### Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in October 2024

| Criterion | Quoted record |
| --- | --- |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic or oral agent targeted to IL-12 or IL-23 within 6 months or any TNFα inhibitor within 2 months or IL-17 within 4 months” |

Source: [ClinicalTrials.gov NCT06588738 version 1](https://clinicaltrials.gov/study/NCT06588738?tab=history&a=1)

<a id="topic-3.1.2.4-5"></a>

#### Cardiac, infection, laboratory, and corticosteroid exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| QTcF | “Patients with QTcF >450 msec (males) or >470 msec (females) at Screening” |
| Cardiovascular disease | “Unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months” |
| Herpes zoster and herpes simplex | “Evidence of recent or recurrent herpes zoster or herpes simplex viral infection” |
| Active or chronic infection | “Evidence of active infection or positive test result for hepatitis B, hepatitis C, HIV or TB” |
| Serious infection history | “History of serious bacterial, fungal, or viral infections that led to hospitalization, or any recent serious infection requiring antibiotic treatment” |
| Immunodeficiency | “Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the patient's immune status” |
| Laboratory abnormalities | “Lab abnormalities indicating significant renal, hepatic or bone marrow dysfunction” |
| Systemic corticosteroids | “History of any immune-mediated or inflammatory medical condition for which patient requires current systemic corticosteroids” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Quoted record |
| --- | --- |
| Experimental: ESK-001 | “ESK-001 administered as an oral tablet” |
| Placebo comparator | “Matching oral placebo” |
| Active comparator: apremilast | “Apremilast administered as an oral capsule” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using PASI 75 and sPGA 0/1 Response as the Co-primary Endpoints

<a id="topic-3.1.2.6.1-1"></a>

##### Primary outcome in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary outcome measure | “To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo” |
| Measure description | “Proportion of patients achieving ≥75% reduction in PASI score. Proportion of patients achieving a score of 0 or 1 on sPGA.” |
| Time frame | “16 weeks” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.6.1-2"></a>

##### Secondary outcomes in the ClinicalTrials.gov record

| Secondary outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast” | “Proportion of patients achieving of ≥90% or 100% reduction in PASI” | “24 weeks” |
| “To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast” | “Proportion of patients achieving of ≥75% reduction in PASI” | “24 weeks” |
| “To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast” | “Proportion of patients achieving a score of 0 or 1 on sPGA” | “24 weeks” |
| “To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast” | “Change from baseline in %BSA” | “24 weeks” |
| “To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast” | “Proportion of patients achieving a score of 0 or 1 on ssPGA” | “24 weeks” |
| “To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast” | “Proportion of patients achieving a score of 0” | “24 weeks” |
| “To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast” | “Proportion of patients achieving a score of 0 or 1” | “24 weeks” |
| “To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo” | “Change from baseline in Pruritus NRS (scale is from 0 (no pain) to 10 (severe pain)).” | “24 weeks” |
| “Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “24 weeks” |
| “To characterize the pharmacokinetics of ESK-001” | “Maximum [Cmax] and minimum [Cmin] plasma concentration” | “24 weeks” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.6.1-3"></a>

##### Regulatory guidance on the clinical meaning of PASI 75 response and on global assessment scales

> “Up till now, there is no generally accepted definition of what constitutes meaningful clinical improvement in psoriasis.”
> “In clinical trials using PASI, both >50% and >75% improvements compared to baseline have been considered as clinically meaningful.”
> “Physician’s global assessment of improvement (PGA or other global score if adequately validated): global assessment of the patient’s overall severity of the disease on 6 or 7-point scale”

Source: [EMA psoriasis clinical investigation guideline (2004)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 862”

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.7.1-2"></a>

##### Planned enrollment at registration

| Field | Quoted record |
| --- | --- |
| Enrollment | “840 [Estimated]” |

Source: [ClinicalTrials.gov NCT06588738 version 1](https://clinicaltrials.gov/study/NCT06588738?tab=history&a=1)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline demographics and disease characteristics by arm in ONWARD2

| Characteristic | Envudeucitinib 40 mg BID, n = 433 | Placebo, n = 211 | Apremilast 30 mg BID, n = 215 |
| --- | --- | --- | --- |
| Age, years, mean (SD) | “48.3 (13.1)” | “49.5 (13.3)” | “48.0 (12.8)” |
| Age group, ≥65 years, n (%) | “51 (11.8)” | “28 (13.3)” | “20 (9.3)” |
| Sex, male, n (%) | “283 (65.4)” | “135 (64.0)” | “135 (62.8)” |
| Race, White, n (%) | “388 (89.6)” | “181 (85.8)” | “193 (89.8)” |
| Race, Asian, n (%) | “10 (2.3)” | “10 (4.7)” | “7 (3.3)” |
| Race, other, n (%) | “35 (8.1)” | “20 (9.5)” | “15 (7.0)” |
| Weight, kg, mean (SD) | “92.3 (23.8)” | “91.1 (23.1)” | “90.8 (19.9)” |
| BMI, kg/m2, mean (SD) | “31.2 (7.8)” | “31.1 (7.3)” | “30.9 (5.9)” |
| Duration of disease, years, mean (SD) | “19.0 (13.5)” | “20.2 (14.5)” | “18.7 (14.5)” |
| PASI, mean (SD) | “20.6 (8.3)” | “21.8 (9.0)” | “20.4 (8.4)” |
| sPGA of 4, n (%) | “131 (30.3)” | “70 (33.2)” | “53 (24.7)” |
| BSA % affected, mean (SD) | “25.2 (14.7)” | “27.3 (16.7)” | “25.8 (14.1)” |
| DLQI, mean (SD) | “10.8 (7.0)” | “10.8 (6.8)” | “9.7 (7.1)” |
| Worst pruritus NRS, mean (SD) | “6.4 (2.6)” | “6.4 (2.4)” | “6.0 (2.7)” |
| Prior systemic psoriasis treatment, n (%) | “213 (49.2)” | “105 (49.8)” | “102 (47.4)” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.2.8.2-2"></a>

##### Baseline itch and scalp involvement by arm in ONWARD2

| Characteristic | Envudeucitinib 40 mg BID, N = 433 | Placebo, N = 211 | Apremilast 30 mg BID, N = 215 |
| --- | --- | --- | --- |
| Worst pruritus NRS ≥1, n (%) | “400 (92.4)” | “200 (94.8)” | “199 (92.6)” |
| Worst pruritus NRS ≥4, n (%) | “345 (79.7)” | “180 (85.3)” | “170 (79.1)” |
| ss-PGA ≥3, n | “285” | “140” | “134” |
| Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%) | “231 (81.1)” | “122 (87.1)” | “108 (80.6)” |

Source: [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### PASI 75, PASI 90, and PASI 100 response rates at week 16 in ONWARD2

| Week 16 response, % | Envudeucitinib 40 mg BID, n = 433 | Placebo, n = 211 | Apremilast 30 mg BID, n = 215 |
| --- | --- | --- | --- |
| PASI 75 (co-primary endpoint) | “70.4” | “13.7” | “38.6” |
| PASI 90 | “53.1” | “4.3” | “20.9” |
| PASI 100 | “27.7” | “0.9” | “7.9” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.2.8.3-2"></a>

##### PASI 75, PASI 90, and PASI 100 response rates at week 24 in ONWARD2

| Week 24 response, % | Envudeucitinib 40 mg BID, n = 433 | Apremilast 30 mg BID, n = 215 |
| --- | --- | --- |
| PASI 75 | “75.1” | “43.3” |
| PASI 90 | “62.1” | “25.6” |
| PASI 100 | “39.5” | “13.0” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

- ONWARD2-specific results are limited to baseline characteristics and PASI 75, PASI 90, and PASI 100 rates at weeks 16 and 24 in one congress presentation. The report holds no description of the ONWARD2 analysis sets, participant disposition, patient-reported outcomes, or safety for ONWARD2 alone, and no ONWARD2 sPGA 0/1 rate.
- The ClinicalTrials.gov record gives an actual enrollment of 862 participants; the congress presentation gives arm sizes of 433, 211, and 215.
- The ClinicalTrials.gov record reads “No Results Posted”, with a certification/extension first submitted on 2026-08-06.
- Asian participants made up 10 (2.3%), 10 (4.7%), and 7 (3.3%) of the envudeucitinib, placebo, and apremilast arms, and White participants 388 (89.6%), 181 (85.8%), and 193 (89.8%).
- Baseline sPGA of 4 was recorded in 131 (30.3%), 70 (33.2%), and 53 (24.7%) participants of the envudeucitinib, placebo, and apremilast arms, and mean baseline PASI was 20.6, 21.8, and 20.4.

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738); [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
